Video Experimental Relacionado

Updated: Sep 9, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Una nueva era en la prevención y el tratamiento de la tuberculosis: avances en el desarrollo de fármacos y

Chun-Yan Zhao^1,2, Chang Song^1,2, Yi-Bo Lu³

¹Department of Tuberculosis, The Fourth People's Hospital of Nanning, Nanning, 530023, Guangxi, China.

Infectious diseases and therapy

|September 3, 2025

Resumen

El desarrollo de medicamentos para la tuberculosis muestra un aumento significativo en los ensayos clínicos, particularmente entre 2018 y 2023. A pesar de los nuevos agentes, las drogas tradicionales dominan, con una distribución desigual de los recursos de investigación a nivel mundial que necesita atención para lograr un progreso equitativo.

Área de la Ciencia:

* Investigación en salud global
* Desarrollo farmacéutico
* Ensayos clínicos de enfermedades infecciosas

Sus antecedentes:

* La tuberculosis (TB) sigue siendo un problema de salud mundial crítico, que requiere una innovación continua en las estrategias de prevención y tratamiento.
* Falta una visión sistemática del panorama actual de ensayos clínicos para el desarrollo de fármacos contra la tuberculosis, lo que dificulta la planificación estratégica.
* Los recientes avances en el desarrollo de fármacos requieren una evaluación de su valor científico y su impacto global.

Objetivo del estudio:

* Revisar sistemáticamente los avances recientes en el desarrollo de fármacos para la tuberculosis.
* Evaluar el valor científico y el impacto global de estos avances.
* Proporcionar información para los médicos y los responsables políticos involucrados en el control de la tuberculosis.

Principales métodos:

* Búsqueda sistemática de la base de datos farmacéutica INFORMA para los ensayos clínicos relacionados con la tuberculosis.
* Inclusión de estudios de intervención con mecanismos detallados de fármacos o objetivos terapéuticos.
* Evaluación, extracción y análisis estadístico descriptivo de las características del ensayo.

Principales resultados:

* Se observó un aumento significativo en los ensayos clínicos de tuberculosis entre 1990 y 2025, con un pico entre 2018 y 2023.
* China y Sudáfrica lideraron la actividad de investigación; Estados Unidos y el Reino Unido completaron los ensayos.
* Las drogas tradicionales dominaron las tuberías, aunque Bedaquiline mostró un rápido avance; las instituciones académicas fueron los principales financiadores.

Conclusiones:

* El panorama del desarrollo de fármacos contra la tuberculosis es dinámico, con un crecimiento notable de los ensayos clínicos y disparidades regionales en la investigación.
* La inversión sostenida, la asignación equitativa de recursos y el compromiso político son cruciales para acabar con la TB.
* Los esfuerzos mundiales coordinados son esenciales para inaugurar una nueva era de prevención y tratamiento de la tuberculosis.

Palabras clave:

Ensayos clínicos Desarrollo de drogas Perspectivas de desarrollo Asignación de recursos La tuberculosis

Más Videos Relacionados

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Videos de Conceptos Relacionados

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories: